Miragen Therapeutics Inc Share Price Nasdaq
Equities
US8266402036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
06-11 | Sector Update: Health Care Stocks Mixed Premarket Tuesday | MT |
06-11 | Sector Update: Health Care | MT |
Sales 2024 * | 349K 26.95M | Sales 2025 * | 305K 23.52M | Capitalization | 938M 72.39B |
---|---|---|---|---|---|
Net income 2024 * | -230M -17.76B | Net income 2025 * | -270M -20.85B | EV / Sales 2024 * | 1,361 x |
Net cash position 2024 * | 462M 35.7B | Net cash position 2025 * | 625M 48.27B | EV / Sales 2025 * | 1,025 x |
P/E ratio 2024 * |
-3.96
x | P/E ratio 2025 * |
-3.68
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.26% |
Latest transcript on Miragen Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 29/10/23 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 30/04/23 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/12/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 02/01/18 |
Tomas Kiselak
CHM | Chairman | 37 | 27/10/20 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 29/10/23 |
1st Jan change | Capi. | |
---|---|---|
+24.45% | 46.56B | |
+45.04% | 41.67B | |
-0.99% | 41.16B | |
+34.87% | 32.4B | |
+21.10% | 28.18B | |
-6.35% | 28.1B | |
+49.46% | 14.52B | |
+47.93% | 13.74B | |
+0.09% | 12.17B |